CST3 and prostate carcinoma: After excluding the first 4 years of follow-up the 95% confidence intervals were wider and only cystatin-C and phosphate were associated with prostate cancer risk after controlling for multiple testing (HR per 1 SD increase 0.93, 0.89–0.97; and 1.07, 1.05–1.29, respectively; Table 3).